sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Supplemental material, sj-pdf-1-tan-10.1177_1756286420987941 for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson...

Full description

Bibliographic Details
Main Authors: Ludwig Kappos (253872), Stanley Cohan (3486812), Douglas L. Arnold (8832665), Randy R. Robinson (10209523), Joan Holman (5170199), Sami Fam (10209526), Becky Parks (8774170), Shan Xiao (3117867), Wanda Castro-Borrero (5339651)
Format: Other Non-Article Part of Journal/Newspaper
Language:unknown
Published: 2021
Subjects:
Neurology and Neuromuscular Diseases
Pharmacology and Pharmaceutical Sciences not elsewhere classified
autoimmunity
daclizumab
encephalitis
multiple sclerosis
sami
Online Access:https://doi.org/10.25384/sage.14131909.v1
id ftsmithonian:oai:figshare.com:article/14131909
record_format openpolar
spelling ftsmithonian:oai:figshare.com:article/14131909 2023-05-15T18:11:41+02:00 sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination Ludwig Kappos (253872) Stanley Cohan (3486812) Douglas L. Arnold (8832665) Randy R. Robinson (10209523) Joan Holman (5170199) Sami Fam (10209526) Becky Parks (8774170) Shan Xiao (3117867) Wanda Castro-Borrero (5339651) 2021-02-26T12:00:00Z https://doi.org/10.25384/sage.14131909.v1 unknown https://figshare.com/articles/journal_contribution/sj-pdf-1-tan-10_1177_1756286420987941_Supplemental_material_for_Safety_and_efficacy_of_daclizumab_beta_in_patients_with_relapsing_multiple_sclerosis_in_a_5-year_open-label_study_EXTEND_final_results_following_early_termination/14131909 doi:10.25384/sage.14131909.v1 CC BY-NC 4.0 CC-BY-NC Neurology and Neuromuscular Diseases Pharmacology and Pharmaceutical Sciences not elsewhere classified autoimmunity daclizumab encephalitis multiple sclerosis Text Journal contribution 2021 ftsmithonian https://doi.org/10.25384/sage.14131909.v1 2021-03-23T17:48:50Z Supplemental material, sj-pdf-1-tan-10.1177_1756286420987941 for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson, Joan Holman, Sami Fam, Becky Parks, Shan Xiao and Wanda Castro-Borrero in Therapeutic Advances in Neurological Disorders Other Non-Article Part of Journal/Newspaper sami Unknown
institution Open Polar
collection Unknown
op_collection_id ftsmithonian
language unknown
topic Neurology and Neuromuscular Diseases
Pharmacology and Pharmaceutical Sciences not elsewhere classified
autoimmunity
daclizumab
encephalitis
multiple sclerosis
spellingShingle Neurology and Neuromuscular Diseases
Pharmacology and Pharmaceutical Sciences not elsewhere classified
autoimmunity
daclizumab
encephalitis
multiple sclerosis
Ludwig Kappos (253872)
Stanley Cohan (3486812)
Douglas L. Arnold (8832665)
Randy R. Robinson (10209523)
Joan Holman (5170199)
Sami Fam (10209526)
Becky Parks (8774170)
Shan Xiao (3117867)
Wanda Castro-Borrero (5339651)
sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
topic_facet Neurology and Neuromuscular Diseases
Pharmacology and Pharmaceutical Sciences not elsewhere classified
autoimmunity
daclizumab
encephalitis
multiple sclerosis
description Supplemental material, sj-pdf-1-tan-10.1177_1756286420987941 for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination by Ludwig Kappos, Stanley Cohan, Douglas L. Arnold, Randy R. Robinson, Joan Holman, Sami Fam, Becky Parks, Shan Xiao and Wanda Castro-Borrero in Therapeutic Advances in Neurological Disorders
format Other Non-Article Part of Journal/Newspaper
author Ludwig Kappos (253872)
Stanley Cohan (3486812)
Douglas L. Arnold (8832665)
Randy R. Robinson (10209523)
Joan Holman (5170199)
Sami Fam (10209526)
Becky Parks (8774170)
Shan Xiao (3117867)
Wanda Castro-Borrero (5339651)
author_facet Ludwig Kappos (253872)
Stanley Cohan (3486812)
Douglas L. Arnold (8832665)
Randy R. Robinson (10209523)
Joan Holman (5170199)
Sami Fam (10209526)
Becky Parks (8774170)
Shan Xiao (3117867)
Wanda Castro-Borrero (5339651)
author_sort Ludwig Kappos (253872)
title sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_short sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_full sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_fullStr sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_full_unstemmed sj-pdf-1-tan-10.1177_1756286420987941 – Supplemental material for Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination
title_sort sj-pdf-1-tan-10.1177_1756286420987941 – supplemental material for safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (extend): final results following early termination
publishDate 2021
url https://doi.org/10.25384/sage.14131909.v1
genre sami
genre_facet sami
op_relation https://figshare.com/articles/journal_contribution/sj-pdf-1-tan-10_1177_1756286420987941_Supplemental_material_for_Safety_and_efficacy_of_daclizumab_beta_in_patients_with_relapsing_multiple_sclerosis_in_a_5-year_open-label_study_EXTEND_final_results_following_early_termination/14131909
doi:10.25384/sage.14131909.v1
op_rights CC BY-NC 4.0
op_rightsnorm CC-BY-NC
op_doi https://doi.org/10.25384/sage.14131909.v1
_version_ 1766184322700673024

Similar Items